1.68 (-%)
As of Nov 21, 2024
Source:
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM inoncology and inflammation. Our lead asset, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United Statesand Australia.
| Country | United States |
| Headquarters | los angeles, california |
| Phone Number | (888) 958-1084 |
| Industry | |
| CEO | Ilya Rachman |
| Website | www.immixbio.com |